Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia
Open Access
- 4 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Cell International
- Vol. 20 (1), 1-13
- https://doi.org/10.1186/s12935-020-01213-y
Abstract
We used bioinformatic tools to dichotomize 157 non-M3 AML patients from the TCGA dataset based on the presence or absence of TP53 mutations, and screened out a key gene related to TP53 mutation for future analysis. DEGs were analyzed by R package “DESeq2” and then run GSEA, GO enrichment, KEGG pathway and PPI network. Hub genes were selected out according to MCC. Log-rank (Mantel–Cox) test was used for survival analysis. Mann–Whitney U’s nonparametric t test and Fisher’s exact test was used for continuous and categorical variables respectively. p value< 0.05 was considered to be statistical significance. TNFRSF4 was final screened out as a key gene. Besides TP53 mutation (p = 0.0118), high TNFRSF4 was also associated with FLT3 mutation (p = 0.0102) and NPM1 mutation (p = 0.0024). Elevated TNFRSF4 was significantly related with intermediate (p = 0.0004) and poor (p = 0.0011) risk stratification as well as relapse statute (p = 0.0099). Patients with elevated TNFRSF4 expression had significantly shorter overall survival (median survival: 2.35 months vs. 21 months, p < 0.0001). Based on our clinical center data, TNFRSF4 expression was significantly higher in non-M3 AML patients than HDs (p = 0.0377) and MDS patients (EB-1, 2; p = 0.0017). Elevated TNFRSF4 expression was associated with TP53, FLT3 and NPM1 mutation as well as poor clinical outcome. TNFRSF4 expression was significantly higher in non-M3 AML patients than HDs and MDS (EB-1, 2) patients. TNFRSF4 is need for future functional and mechanistic studies to investigate the role in non-M3 AML.Keywords
Funding Information
- National Natural Science Foundation of China (81770172)
- Natural Science Foundation of Jiangsu Province (BE2017747)
- iangsu Province "333" project (BRA2019103)
- Fundamental Research Funds for Central Universities of the Central South University (2242019K3DZ02)
- Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology (2017)
- Key Medical of Jiangsu Province (ZDXKB2016020)
This publication has 38 references indexed in Scilit:
- Application of ggplot2 to Pharmacometric GraphicsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus ErythematosusClinical and Developmental Immunology, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor MicroenvironmentCancer Research, 2010
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in MiceJournal of Immunotherapy, 2010
- The significance of OX40 and OX40L to T‐cell biology and immune diseaseImmunological Reviews, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003